Royalty Report: Drugs, Cancer, Pharmaceuticals – Collection: 28127


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Drugs
  • Cancer
  • Pharmaceuticals
  • Biotechnology
  • Antibody
  • Disease
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28127

License Grant
The Licensee entered into an exclusive collaboration Agreement with the Licensor, for the development and commercialisation of MEDI4736 across a range of blood cancers including non-Hodgkin''s lymphoma, myelodysplastic syndromes and multiple myeloma.
License Property
MEDI4736 is an investigational human monoclonal antibody directed against programmed cell death ligand 1 (PD-L1). Signals from PD-L1 help tumours avoid detection by the immune system. MEDI4736 blocks these signals, countering the tumour's immune-evading tactics. MEDI4736 was accelerated into Phase III clinical development in non-small cell lung cancer and head and neck cancer. The Licensor will also be responsible for global commercialisation of approved treatments.
Field of Use
The Licensee will manufacture and book all sales of MEDI4736 and will pay a royalty to the Licensor on worldwide sales in haematological indications.

IPSCIO Record ID: 28192

License Grant
The Licensor entered into a worldwide, strategic collaboration agreement with the Licensee, to develop and commercialize MEDI4736, a novel anti-PD-L1 monoclonal antibody, for hematologic malignancies. The Licensor also will be responsible for the global commercialization of approved MEDI4736 indications in hematology.
License Property
The Licensor will lead clinical development across all new clinical trials within the collaboration and will be responsible for all costs associated with such trials until December 31, 2016, after which we will be responsible for 75 percent of those costs.  MEDI4736 is a novel anti-PD-L1 monoclonal antibody, for hematologic malignancies.

IPSCIO Record ID: 27631

License Grant
The Licensee has the exclusive right to develop, manufacture and commercialize Opdivo in all territories worldwide except Japan, South Korea and Taiwan (where the Licensor was responsible for all development and commercialization prior to the amendment). The alliance agreement was amended to provide for additional collaboration activities in Japan, South Korea and Taiwan pertaining to Opdivo and several other Licensee compounds including ipilimumab, lirilumab, urelumab and BMS-986016 (anti-LAG3). Both parties have the right and obligation to jointly develop and commercialize the compounds. The Licensee is responsible for supply of the product.
License Property
The agreement is to develop and commercialize Opdivo, an anti-PD-1 human monoclonal antibody being investigated as an anti-cancer treatment. Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the programmed death receptor-1 (PD-1) on T and NKT cells. It is being investigated as an anticancer treatment. It is in Phase III trials (which commenced in 2012) in non-small cell lung cancer, renal cell cancer and melanoma.
Field of Use
The parties jointly own a patent covering Opdivo as a composition of matter that expires in 2027 in the U.S. (excluding potential patent term extension). In December 2014, the FDA approved Opdivo for unresectable (inoperable) or metastatic melanoma, and disease progression following Yervoy and, if BRAF V600 mutation positive, a BRAF inhibitor. Opdivo was also approved in Japan in July 2014 for the same indication. The FDA has granted Fast Track designation for Opdivo in three tumor types non-small cell lung cancer, renal cell carcinoma and metastatic melanoma, and it is in the registrational process for melanoma and non-small cell lung cancer in the U.S. and Europe. The FDA granted Breakthrough Therapy designation for Hodgkin Lymphoma in 2014.

IPSCIO Record ID: 271809

License Grant
The Licensor of Denmark grants an exclusive development, manufacturing and commercialization is a global license for daratumumab.
License Property
Daratumumab, marketed as DARZALEX, is a human IgG1k monoclonal antibody, or mAb, that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of MM cells.
Field of Use
Daratumumab is for the Treatment of Multiple Myeloma.
Multiple myeloma, also known as plasma cell myeloma, is a cancer of plasma cells, a type of white blood cell which normally produces antibodies.

IPSCIO Record ID: 211579

License Grant
The Company received exclusive development and commercialization rights worldwide to MGA012, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1). MGA012 is currently in clinical development by Licensor.
License Property
MGA012 is an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1). MGA012 is currently in clinical development by Licensor.
Field of Use
This agreement pertains to the drug industry.
Antibodies targeting PD-1 have shown clinical efficacy in the treatment of various tumors. These antibodies act as checkpoint inhibitors, releasing the “brakes” on the immune system that are often imposed by tumors as a means to evade immune detection.

IPSCIO Record ID: 325366

License Grant
Through a partnership with a third party, Licensee develops and/or commercialize sugemalimab for worldwide sales which results in royalty payments to Licensor.
License Property
Sugemalimab (CS1001), an OmniAb-derived anti-PD-L1 monoclonal antibody used in combination with chemotherapy for lung cancer.
Field of Use
Field of use is for the first-line treatment of advanced squamous and non-squamous non-small cell lung cancer (“NSCLC”).

Lung cancer is a type of cancer that starts in the lungs. Cancer starts when cells in the body begin to grow out of control. The main subtypes of NSCLC Lung Cancer are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.

IPSCIO Record ID: 26237

License Grant
The agreement granted exclusive development and commercialization rights to the Licensor's fully human, immune-oncology anti-PD-L1 monoclonal antibody (mAb) STI-A1014 for the greater Chinese market.
License Property
The mAb is novel, proprietary, and fully human. The Licensor is currently developing production quality cell lines for their anti-PD-L1 antibody, STI-A1010, which will lay the foundation for Investigational New Drug, or IND, -enabling studies in the U.S. in 2014. The Licensor anticipates that a Phase I clinical trial for their lead candidate anti-PD-L1 antibody could be initiated in 2015.  The mAb's are derived from the Licensor's proprietary G-MAB® library platform and chosen based on cancer targets.

Patent Antigen binding proteins that bind PD-L1

Field of Use
The individual mAbs discovered from the Licensor's library potentially give a multitude of therapeutic options to target and attack cancer cells. This could be either directly, such as (i) recruitment of immune effector functions, including, but not limited to, antibody-dependent cellular cytotoxicity, or ADCC, or (ii) antagonistic suppression of cellular signaling processes required for cancer proliferation and metastasis; or indirectly, via modulation host biology, such as (a) enhancement of immune activity in the tumor, or (b) normalization of the tumor microenvironment, including anti-angiogenesis for cutting off blood supplies to the tumor.

IPSCIO Record ID: 290082

License Grant
The Company was granted an exclusive license to develop and commercialize envafolimab for the treatment of sarcoma in North America from Chinese Licensor.

The Company is responsible for conducting, and will bear the costs of, any Phase 1, Phase 2, Phase 3, or post-approval clinical trial in North America for envafolimab in the indications of refractory and first line treatment of soft tissue sarcoma. Licensees are responsible for conducting, and will bear the costs of, IND-enabling studies (other than those specific to the sarcoma indication) and the preparation of CMC activities sections of an investigational new drug (IND) application for envafolimab. Licensees have agreed to manufacture and supply, or to arrange for a third party manufacturer to manufacture and supply, envafolimab to the Company at pre-negotiated prices that vary based on clinical or commercial use. Licensees retained the right to develop envafolimab in all territories outside of North America as well as within North America for all indications other than soft tissue sarcoma.

License Property
Envafolimab is an investigational single-domain antibody (“sdAb”) with affinity to PD-L1 administered by subcutaneous injection without an adjuvant.  Envafolimab is being developed by Licensee for the treatment of various cancer indications.  Envafolimab is a camelid IgG4 single domain antibody with single digit nanomolar affinity to PD-L1.

Envafolimab, which is also known as KN035, is an investigational PD-L1 single domain antibody administered by subcutaneous injection, for the treatment of soft tissue sarcoma in North America.

Single-domain antibodies are a novel class of therapeutic protein that contain the unique structural and functional properties of naturally-occurring heavy chains and lack light chains.  On February 6, 2019, the FDA approved the first single-domain antibody, Cablivi® (caplacizumab), for adults with acquired thrombotic thrombocytopenic purpura.

PD-L1 is an immune-inhibitory checkpoint molecule expressed on epithelial and vascular endothelial cells, as well as by a number of immune cells, and is utilized by tumor cells as an immune escape mechanism.

Field of Use
Envafolimab is also known as KN035, an investigational PD-L1 single domain antibody administered by subcutaneous injection, for the treatment of soft tissue sarcoma.

Sarcoma is the general term for a broad group of cancers that begin in the bones and in the soft (also called connective) tissues (soft tissue sarcoma).

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.